Neoplasms Clinical Trial
— ACS CARESOfficial title:
Community Engagement in the Development of Oncology Navigation Training
Verified date | February 2024 |
Source | American Cancer Society, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this study is to evaluate the pilot phase of ACS Cares to identify key implementation outcomes and assess effectiveness of the program to improve distress, enhance communication, and reduce missed appointments and healthcare utilization.
Status | Enrolling by invitation |
Enrollment | 2000 |
Est. completion date | December 31, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - patients of health system's healthcare physician champions with a confirmed cancer diagnosis - patients with a confirmed cancer diagnosis - families of patients with a confirmed cancer diagnosis - Caregivers of patients with a confirmed cancer diagnosis Exclusion Criteria: - patients, families and/or caregivers without a confirmed cancer diagnosis - patients not receiving care from healthcare physician champions |
Country | Name | City | State |
---|---|---|---|
United States | Medical University Hospital Authority, Hollings Cancer Center | Charleston | South Carolina |
United States | University of Iowa Health Care | Iowa City | Iowa |
United States | American Cancer Society | Kennesaw | Georgia |
United States | UCLA Health | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
American Cancer Society, Inc. | University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure the impact of ACS CARES on patient-reported outcomes: SDOH barriers | SDOH barriers | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Information Needs | Information Needs | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Distress needs | Distress needs | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Satisfaction with program | Satisfaction with program | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Unmet needs | Unmet needs | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Patient-provider communication | Patient-provider communication | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: clinical trials knowledge | clinical trials knowledge | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Patient activation | Patient activation | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Financial toxicity | Financial toxicity | Baseline and 6 months into pilot | |
Primary | Measure the impact of ACS CARES on patient-reported outcomes: Quality of life | Quality of life | Baseline and 6 months into pilot | |
Primary | Context, Training, and Process Measures: Service Penetrance and Process Measures: Service Penetrance | • # of patients/caregivers approached for ACS CARES Median and range per volunteer • # of patients/caregivers who decline by refusal reason • # of patients/caregivers supported by ACS CARES Median and range per volunteer • # of patients/caregivers who received psychosocial distress screening Median and range per ACS CARES volunteer • # of patients/caregivers who received an SDOH screening Median and range per ACS CARES volunteer • # of follow-ups conducted Median and range per ACS CARES volunteer • # of in-person visits conducted Median and range per ACS CARES volunteer • # of shifts completed Median and range per ACS CARES volunteer • # of referrals received from health system team members | through study completion, an average of 1 year | |
Secondary | Sociodemographic differences between ACS CARES supported and non-ACS CAREs supported patients | Patient characteristics: age, sex, gender (if available), race, ethnicity, insurance status, zip code, urban or rural residence, Area Deprivation Index category, and distance from cancer center (<30 minutes, 30-60 minutes, >60 minutes) | baseline and 1 year | |
Secondary | Impact of ACS CARES on treatment adherence and healthcare | Cancer and treatment characteristics: cancer type, date of diagnosis, type of current treatment (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Stem Cell or Bone Marrow Transplant, Hormone Therapy), total clinic appointments, # clinic appts missed/cancelled, total infusion appointments, # infusion appointments missed/cancelled, total radiation treatment appts, # radiation treatment appointments missed/cancelled, enrolled in a clinical trial (y/n), start date of clinical trial participation, ER visits, hospitalizations, ICU admissions, total cost of care. For new patients during baseline or intervention time periods, date of first clinic visit. | baseline and 1 year | |
Secondary | Context, Training, and Process Measures: Volunteer Satisfaction | Volunteer Satisfaction Index | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |